Inflammation marker related to obesity is elevated in patients with pancreatic cancer

Feb 03, 2010

The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.

Studies have shown that obesity is correlated with . Similarly, studies have also shown that inflammation contributes to the of pancreatic ductal adenocarcinoma (PDA). This study looks at the role of monocyte chemoattractant protein-1 (MCP-1), a marker of inflammation, in with pancreatic cancer.

Hwyda Arafat, M.D., Ph.D., associate professor of Surgery at Jefferson Medical College of Thomas Jefferson University, and colleagues sought to identify whether MCP-1 could serve as a marker for pancreatic cancer, and a differentiation marker between benign and malignant lesions.

The research team analyzed the MCP-1 levels in serum samples obtained from patients with confirmed PDA or intraductal papillary mucinous neoplasms (IPMN). They found that the levels of MCP-1 were significantly elevated in extremely obese patients. In the less obese population (BMI < 37.5), the mcp-1 levels were elevated only in patients with pda. in the patients who had ipmn, high levels of mcp-1 also correlated with older age.

"MCP-1 has potential as a for pancreatic cancer, but this needs to be confirmed in a larger sample size," Dr. Arafat said. "Further study of this protein in a larger sample size and different benign and unresectable is needed. Understanding the nature of the relationship of its elevation with age and the highest levels of obesity will assist with the full development of the potential clinical usage of this marker."

Explore further: The fine line between breast cancer and normal tissues

add to favorites email to friend print save as pdf

Related Stories

Smoking increases potential for metastatic pancreatic cancer

Jul 27, 2009

Smoking has once again been implicated in the development of advanced cancer. Exposure to nicotine by way of cigarette smoking may increase the likelihood that pancreatic ductal adenocarcinoma will become metastatic, according ...

IDO2 an active enzyme to target in pancreatic cancer

Dec 01, 2008

An enzyme that is overexpressed in pancreatic cancer cells may hold the key to successfully treating the disease with targeted immunotherapy, researchers from Thomas Jefferson University reported at the 2008 Annual Meeting ...

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

2 hours ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

User comments : 0